Valuation: Paradigm Biopharmaceuticals Limited

Market Cap 91.95M 63.96M 55.95M 51.6M 47.66M 90.43M 6.1B 617M 242M 3.01B 240M 235M 10.33B P/E 2026 *
-1.89x
P/E 2027 * -1.89x
Enterprise Value 57.95M 40.31M 35.26M 32.52M 30.04M 57M 3.84B 389M 153M 1.89B 151M 148M 6.51B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
91.43%
Yield 2026 *
-
Yield 2027 * -
1 day+2.94%
Current month+6.06%
1 month+16.67%
3 months-23.91%
6 months-49.28%
Current year-48.53%
1 week 0.16
Extreme 0.16
0.18
1 month 0.16
Extreme 0.155
0.2
Current year 0.14
Extreme 0.135
0.37
1 year 0.14
Extreme 0.135
0.47
3 years 0.14
Extreme 0.135
1.02
5 years 0.14
Extreme 0.135
2.69
10 years 0.14
Extreme 0.135
4.5
Manager TitleAgeSince
Chief Executive Officer - 2022-11-21
Director of Finance/CFO - 2023-03-02
Chief Operating Officer - -
Director TitleAgeSince
Chairman - -
Director/Board Member 60 2020-12-08
Director/Board Member - 2024-03-03
Date Insider Type Main position Quantity % Market Cap.
06-17Free

Chief Executive Officer

176,470 0.0336%
06-17Free

Director

176,470 0.0336%
06-17Free

Chief Executive Officer

176,470 0.0336%
Change 5-day change 1-year change 3-year change Capi.($)
+2.94%0.00%-57.83%-81.58% 62.13M
+0.29%+1.31%+4.14%+10.69% 50.73B
-2.56%-4.12%+374.76%+586.64% 39.73B
+1.72%+1.97%+31.16%-4.38% 34.69B
+2.05%-1.41%+21.00%+53.95% 33.21B
-0.06%-4.63%+2.94%+31.65% 26.76B
-2.36%-1.60% - - 16.8B
-0.37%-5.15%+67.30%+122.93% 15.37B
+0.78%+1.16%+15.53%+17.32% 13.78B
-0.25%-2.05%+11.99%-32.75% 12.85B
Average +0.22%-1.17%+52.33%+78.28% 24.4B
Weighted average by Cap. +0.01%-0.38%+80.80%+123.42%

Financials

2026 *2027 *
Net sales - -
Net income -36.3M -25.25M -22.09M -20.37M -18.81M -35.7M -2.41B -243M -95.58M -1.19B -94.8M -92.74M -4.08B -44.8M -31.16M -27.26M -25.14M -23.22M -44.06M -2.97B -300M -118M -1.46B -117M -114M -5.03B
Net Debt -34M -23.65M -20.69M -19.08M -17.62M -33.44M -2.26B -228M -89.53M -1.11B -88.79M -86.86M -3.82B -12M -8.35M -7.3M -6.73M -6.22M -11.8M -796M -80.46M -31.6M -392M -31.34M -30.66M -1.35B
Logo Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited is a late-stage drug development company engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). PPS is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans. It develops PPS under the brand name Zilosul. Other indications under investigation for PPS include the treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses; treating alphavirus-induced arthralgia; chronic heart failure; acute respiratory distress syndrome; and allergic respiratory conditions. It is also advancing early formulation development for Pentacoxib, an oral combination of PPS and a COX-2 inhibitor targeting patients with earlier-stage OA.
Employees
-
Date Price Change Volume
26-07-13 A$0.1750 +2.94% 3,381,401
26-07-10 A$0.1700 0.00% 564,494
26-07-09 A$0.1700 0.00% 691,493
26-07-08 A$0.1700 -2.86% 884,472
26-07-07 A$0.1750 0.00% 1,898,099
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1750AUD
Average target price
1.095AUD
Spread / Average Target
+525.71%

Annual profits - Rate of surprise